Does Ro Have Retatrutide? No — Here's What You Can Get Now

By The RX Index Editorial Team · Last verified October 17, 2026

No. Ro does not offer retatrutide. Retatrutide is an investigational Eli Lilly drug, not FDA-approved; Lilly plans to apply in January–March 2027. As of October 17, 2026, Ro lists FDA-approved options like Zepbound, Wegovy and Foundayo. Before approval, access requires a qualifying Lilly trial or narrow, doctor-requested expanded access.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Here's the confusing part. Ro publishes articles about retatrutide, and one still suggests it could arrive in 2026. Below is what Ro actually sells, what changed, and how its available medicines differ from retatrutide.

RX Index Decision Verdict: Ro can't give you retatrutide. It can connect you with a prescriber for the FDA-approved medicines it offers now.

• Best for: adults who want a real, FDA-approved Lilly or Novo Nordisk medicine now, with an online prescriber and insurance help in one place.
• Not ideal for: anyone joining only to get retatrutide, Medicaid members, people who want compounded medication, or people who already have a doctor managing their GLP-1.
• The factor that matters most: whether you'll only accept retatrutide, or you're open to an approved medicine you can start now.

Does Ro have retatrutide right now?

Ro's treatment menu does not include retatrutide, and we found no confirmed Ro launch announcement. Retatrutide has no FDA approval, so it isn't available by ordinary prescription. The trial and expanded-access paths run through Eli Lilly, not through a membership.

We checked Ro's weight-loss menu and pricing page on October 17, 2026. Here's everything you might mean by "Ro has it," in one place.

Ro and retatrutide: what's actually available (checked October 17, 2026)

Want to check it yourself? Open Ro's pricing page, press Ctrl+F (or Cmd+F on a Mac), and type "retatrutide." Nothing comes up.

The right GLP-1 provider isn't the same for everyone. It depends on your state, your insurance and its covered-drug list, whether you want FDA-approved or compounded medicine, a shot or a pill, and your budget. If you're not sure Ro is your fit, The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It's free, takes about 2 minutes, and needs no signup. It doesn't arrange retatrutide or confirm your plan's coverage.

See which available GLP-1 path fits you

Why does Ro have pages about retatrutide?

Ro's health team writes articles about medicines it doesn't sell, including retatrutide. Those articles explain the drug; Ro's treatment menu is what shows what you can actually get. Three of Ro's retatrutide claims are also now out of date.

Say you read Ro's retatrutide guide, then tap a "Get started" button on the same page. That button opens Ro's general weight-loss intake for medicines it already offers. It isn't a retatrutide application.

Here's what Ro's articles say next to what's true today:

None of this means Ro promised you retatrutide. It means those passages don't reflect Lilly's current filing plan or its expanded-access guidance.

Why can't Ro, or anyone, routinely prescribe retatrutide yet?

There's nothing approved to prescribe. Lilly says retatrutide cannot legally be sold or marketed for human use, and FDA says it can't be compounded. A telehealth visit doesn't change either rule.

People usually ask about three workarounds. None of them works:

• Off-label prescribing. That means using an approved drug outside its approved labeling, as FDA explains. Retatrutide has no approval, so there's nothing to prescribe "off" of.
• Compounded retatrutide. Compounding prepares or changes a medicine for a patient's medical needs. Compounded drugs are not FDA-approved. FDA says retatrutide isn't part of any approved drug and can't be used in compounding. FDA has warned telehealth companies, ingredient sellers and outsourcing facilities over retatrutide.
• "Research use only" vials. FDA has warned companies that sold unapproved retatrutide directly to consumers for human use despite a "research" label. It urges consumers not to buy these products.

More detail lives in our guide to why compounded retatrutide isn't legal.

Can you get retatrutide through a trial or early access?

Yes, in narrow cases, but we found no such service through Ro. Lilly runs clinical trials and also reviews early-access requests from treating doctors. Neither one is a retail order or a routine prescription.

Clinical trials

A trial is a research study with its own rules, sites and schedule. Most retatrutide studies have finished enrolling. As of October 17, 2026, the Phase 3 liver study SYNERGY-Outcomes was still listed as recruiting.

You may get a placebo, which is an inactive shot. How likely depends on the study. In TRIUMPH-3, for example, about half of participants were assigned placebo, according to Lilly's July 23 release.

If you're looking, use Lilly's trial finder or search retatrutide studies on ClinicalTrials.gov, then call the study site and ask whether they're screening new people this week. Ask which treatment groups are open; a study listing doesn't promise retatrutide. Our retatrutide trial tracker follows each study's status.

Expanded access (early access)

Expanded access lets a seriously ill patient use an unapproved drug outside a trial. Lilly's program is very narrow. All five of these must be true, per Lilly Medical (last reviewed August 26, 2026):

1. You're 18 or older.
2. Your BMI is 35 or higher despite taking, and being able to tolerate, the highest available dose of a long-term weight-management medicine as directed.
3. You have two or more serious or life-threatening obesity-related health problems and are receiving standard care for them.
4. You can't join a trial of retatrutide or a similar investigational medicine (you don't qualify, or no enrolling site is reasonably close).
5. You and your doctor have talked through every standard option, including weight-loss surgery.

Meeting all five rules does not guarantee access. Lilly also checks medical reasons that would rule treatment out, location and supply.

Your treating doctor starts the request by calling Lilly. If Lilly approves, that doctor must apply to FDA, get an ethics board's approval, store the medicine, and file safety reports. Lilly says it provides the drug at no cost, but your visits and tests can still cost money. Lilly doesn't ship it straight to patients.

We found no Ro service that handles any of this. If your current treatment hasn't been enough, bring the full early-access requirements to the doctor who manages your care.

What can you get through Ro instead?

Ro lists FDA-approved GLP-1 medicines from Eli Lilly and Novo Nordisk. Some are cash-pay only, and some can go through insurance. None of them is retatrutide.

Ro's GLP-1 menu and medicine prices (checked October 17, 2026)

These prices cover a 28-day supply for Zepbound KwikPen or Wegovy pen and a 30-day supply for either pill. KwikPen needles are required and sold separately. The Wegovy pen offer applies to patients new to the Wegovy Savings Offer or NovoCare Pharmacy; signing up by December 31 does not lock the price for later fills.

The $449 upper-dose Zepbound KwikPen and $299 upper-dose Foundayo offers require the next refill purchase within 45 days of the previous delivery. Complete Ro's check-in early enough for the purchase to meet that deadline. Without those refill offers, Lilly lists Zepbound KwikPen at $499 for 7.5 mg and $699 for 10–15 mg, and Foundayo at $349 for 14.5 or 17.2 mg. Foundayo's regular prices at 2.5 and 5.5 mg are $199 and $299 after the temporary discounts end. See the Zepbound terms, Foundayo terms, and NovoCare Wegovy terms.

Ro's membership is a separate charge (see the bill below). Ro says its cash prices match LillyDirect, NovoCare and TrumpRx. Ozempic's label covers type 2 diabetes and specified related risk reductions; weight-loss use is off-label. Ro's menu also links to Saxenda, with no price on its pricing page. A listing doesn't promise a prescription. A Ro-affiliated provider decides what fits you.

For adult weight-loss treatment, a clinician may consider medicine at a BMI of 30 or higher, or 27 or higher with a weight-related condition like high blood pressure, as NIH's patient guide explains. Your health history also matters. These are weight-loss treatment criteria, not a test for every diabetes prescription or insurance decision.

Zepbound shares two targets, but it isn't retatrutide

Zepbound contains tirzepatide, which activates the receptors for two hormones, GIP and GLP-1. Retatrutide activates those two plus the glucagon receptor. Receptors are the parts of cells that respond to these signals. Same company, different medicine.

Here's how their targets differ. The number of targets is not a ranking of how well a medicine will work for you:

More on how Ro sells it: does Ro have tirzepatide?

If you'd rather take a pill

Ro lists two pills: the Wegovy pill and Foundayo. Neither contains retatrutide, and Ro sells both as cash-pay only. If you need insurance to pay, check your own plan's covered-drug list before you pay cash. More here: does Ro have the Wegovy pill?

Start with your own doctor first if: you're under 18, pregnant or planning to be, have type 1 diabetes or a history of an eating disorder. The medicines above also have label-specific reasons not to take them, including a personal or family history of medullary thyroid cancer, MEN 2 (a rare inherited gland condition), or a serious allergy to that medicine. Your doctor can check the Zepbound, Wegovy, Foundayo, or Ozempic label with you.

Should you join Ro now, or wait for retatrutide?

There's no confirmed Ro launch date, and no approval date either. If you'll only take retatrutide, discuss waiting or investigational access with your doctor and agree on when to review the decision. If you want help now, ask about an available treatment rather than waiting on an unknown date.

Four things have to happen before Ro could offer retatrutide as an approved treatment:

Applying FDA's published review goals to a January–March 2027 submission gives a rough decision window of September–November 2027 with priority review, or January–March 2028 with standard review. That assumes FDA accepts the application for filing and the review stays on its original schedule. Neither review type nor a retatrutide decision date has been announced. That's our math, not a promise of approval or a launch date.

Trial results help explain the interest. Counting everyone in each study as assigned, retatrutide 12 mg averaged 25.0% weight loss at 80 weeks in TRIUMPH-1, versus 3.9% with placebo. Zepbound 15 mg averaged 20.9% at 72 weeks in SURMOUNT-1, versus 3.1% with placebo. Both studies involved adults with obesity or overweight without type 2 diabetes. These were separate trials, not a head-to-head test, so those numbers don't show how much more weight one medicine would help you lose. See retatrutide vs tirzepatide for the full comparison.

Find yourself here:

Already on Zepbound or Wegovy? Don't stop or change it to chase a trial. Talk to your prescriber first.

Check the full bill first

Ro charges two separate things: a membership and the medicine. The membership doesn't include medicine, and insurance doesn't pay it. A low "per month" price can mean one big payment up front.

Ro membership prices (checked October 17, 2026; medicine is extra)

The prepaid amounts are our calculations from Ro's rates and billing periods: $99 × 3, $89 × 6, and $74 × 12. The $39 introductory month is separate. Sources: Ro pricing, Ro terms.

Illustrative first-supply subtotals, using Ro's listed prices plus one $39 introductory membership month (our math):

• Zepbound KwikPen, 2.5 mg: $299 + $39 = $338, before pen needles or other charges. One KwikPen holds four weekly doses (28 days).
• Wegovy pill (1.5 mg) or Foundayo (0.8 mg): $149 + $39 = $188 for the first 30-day medicine supply plus introductory membership.
• Wegovy pen, 0.25 mg: $199 + $39 = $238 for the first 28-day medicine supply plus introductory membership, if the offer applies.

Your dose decides your price, and a provider decides your dose. The first supply is not what every refill costs. These are subtotals, not completed checkout quotes; confirm the offer, supplies, taxes, and any other charges before paying. A 28-day supply is shorter than a calendar month.

The fine print, from Ro's terms (revised April 2, 2026):

• The membership renews automatically.
• Once prescribed and enrolled, paid membership fees aren't refundable.
• To stop the next charge, cancel at least 48 hours before renewal.
• If no medicine is ever prescribed, Ro refunds your purchase and doesn't enroll you in the renewing membership. A later insurance denial is not the same as never receiving a prescription.

For dose-by-dose budgets, see our Ro GLP-1 cost breakdown.

If you want help with insurance

Ro's free coverage check covers Ozempic, the Wegovy pen, and the Zepbound single-dose autoinjector pen. It doesn't check retatrutide, the Wegovy pill, Foundayo or the Zepbound KwikPen. If you're prescribed one of those pens through Ro, its team handles the insurer paperwork.

Prior authorization is a permission slip from your insurer when your plan requires one. The insurer checks whether the drug meets its coverage rules. Help with the paperwork doesn't guarantee a yes.

Not sure what kind of plan you have? Look at your insurance card or call the member-services number on the back. Ask whether the exact medicine is covered and what approval steps apply.

A quick self-check before you spend anything. Is your insurance through an employer or the marketplace? Are you considering Ozempic, the Wegovy pen or the Zepbound single-dose pen? Check coverage before you pay cash. You'll enter your name and insurance-card details, then Ro emails a report after checking with your plan. A prescriber still decides whether a medicine fits your health needs.

Check your GLP-1 coverage with Ro

If you're open to a medicine Ro offers now and want an online prescriber, Ro starts by asking whether you'd prefer a pill, a shot, or a provider's recommendation. Look over the membership, the medicine price, and the renewal terms before you pay.

Explore GLP-1 care on Ro

Already have a doctor who can prescribe and follow up? Ask them first. You may not need a second membership. Our Ro vs. LillyDirect comparison shows how that math works.

Someone is selling "Ro retatrutide" or "Reta." Is it real?

No. Ro doesn't sell retatrutide, and Lilly says it can't legally be sold for human use. A consumer offer to buy retatrutide, "Reta" or "GLP-3" isn't an approved medicine or proof of access to Lilly's trial or expanded-access supply.

This isn't just a labeling problem. FDA warns that unapproved retatrutide sold to consumers with a "research" label is of unknown quality and may harm their health. A seller's claim of purity doesn't establish FDA approval or a legal treatment path.

Three quick red flags:

• The seller won't name a licensed pharmacy you can look up.
• The label says "research use only" or "not for human consumption."
• There's no trial site or doctor's early-access paperwork behind it.

If you took a suspect product, call Poison Control at 1-800-222-1222 for advice, even if you feel well. Call 911 if someone collapses, has a seizure, has trouble breathing, or can't be awakened, following Poison Control's first-aid guidance. More: how to avoid fake GLP-1 medicines and Lilly's lawsuits against retatrutide sellers.

What we actually verified

Checked October 17, 2026:

• Ro's weight-loss menu, pricing page, insurance page, free coverage checker, the two retatrutide articles discussed above, and terms of use (revised April 2, 2026).
• Lilly's September 29, 2026 filing update, May 21 TRIUMPH-1 results, July 23 TRIUMPH-3 results, and the current official medicine labels used above.
• The published TRIUMPH-1 journal abstract (September 29, 2026) and NIH's adult weight-loss treatment criteria.
• Lilly, NovoCare and Ro's offer terms, including refill deadlines, supply lengths, prepaid membership periods and separate needle costs.
• Lilly Medical's expanded-access page (last reviewed August 26, 2026), the NCT07629401 expanded-access record, the SYNERGY-Outcomes record, and Lilly's trial finder.
• FDA's unapproved-GLP-1 page (content current as of October 1, 2026), original-application review goals, and Poison Control's first-aid guidance.

What Ro states, which we didn't test: price-matching with LillyDirect, NovoCare and TrumpRx; the $39 refund if you're not eligible.

What we didn't do: we didn't sign up, get a prescription, or check anyone's coverage.

What we couldn't confirm: any future Ro plans, a retatrutide price, your eligibility, a specific trial site's screening, or your exact checkout total.

For your own next step, use the coverage check above, review the full checkout total, or call the trial site before you commit.

This page uses the RX Index Decision Verdict for one availability question. For our full take on Ro, read our Ro GLP-1 reviews and see how we evaluate treatment paths.

Frequently asked questions

Should I start Zepbound now or try for a retatrutide trial?

It depends on your health needs and whether a real study fits your history and location. Few retatrutide studies are still enrolling, and some assign placebo. Talk through both with your doctor before changing anything. Being interested in a trial doesn't mean you'd qualify.

Could I get a placebo in a retatrutide trial?

Yes, depending on the study. In TRIUMPH-3, about half of participants got placebo. Ask the study team which treatments are involved before you enroll.

Does Ro have retatrutide?

No. Ro's menu didn't list it on October 17, 2026, and Lilly says retatrutide can't legally be sold for human use yet.

Will Ro offer retatrutide after it's approved?

We found no Ro announcement. Ordinary prescribing would require FDA approval after Lilly applies, currently planned for Q1 2027. Ro already sells Lilly's Zepbound and Foundayo through Lilly's self-pay program, so it's a plausible future seller. That's our guess, not Ro's promise.

Can a Ro doctor prescribe retatrutide off-label?

No. Off-label use only applies to a drug that's already approved. Retatrutide isn't.

Is there a Ro retatrutide waitlist?

We found none on Ro's public pages. A waitlist anywhere doesn't put you in line with FDA or Lilly.

Is Ro's $39 offer the price of retatrutide?

No. That's Ro's first-month membership fee. Medicine costs extra, and Ro doesn't offer retatrutide at any price.

Can another telehealth company get me compounded retatrutide?

No. FDA says retatrutide can't be used in compounding under federal law. A clinic website or a "research" label doesn't change that.

When will retatrutide be available?

There's no confirmed launch date. If Lilly submits in Q1 2027 and FDA accepts the filing, our calculation from FDA's review goals gives September–November 2027 for priority review or January–March 2028 for standard review, without a schedule extension. Neither is an announced retatrutide deadline or a promise of approval. Approval also isn't the same day as pharmacy stock.

How much will retatrutide cost?

Lilly hasn't announced a commercial price, and any price you see online isn't for an approved product. Our retatrutide cost predictions explain what might shape it.

Can I switch from Zepbound to retatrutide later?

If retatrutide is approved, that would be a decision for you and your prescriber then. Here's what's known so far about switching from tirzepatide to retatrutide.

Does Ro take insurance?

Ro's membership is cash-only. Its insurance team works on getting the medicine covered for the Ozempic, Wegovy and Zepbound pens. See does Ro accept insurance for GLP-1s?

Sources

• Ro — Weight-loss menu (Ro Body), pricing, insurance and free insurance coverage checker; checked Oct 17, 2026
• Ro — Terms of Use, revised Apr 2, 2026; checked Oct 17, 2026
• Ro — How to get retatrutide, updated Aug 27, 2026, and What is retatrutide?, updated Apr 2, 2026; checked Oct 17, 2026
• Eli Lilly — September filing update and TRIUMPH-2 results, Sept 29, 2026; checked Oct 17, 2026
• Eli Lilly — TRIUMPH-1 results, May 21, 2026, and two additional Phase 3 trial results, Jul 23, 2026; checked Oct 17, 2026
• Jastreboff and colleagues — Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity, New England Journal of Medicine, Sept 29, 2026; published abstract checked Oct 17, 2026
• NIH/NIDDK — Prescription medications to treat overweight and obesity, last reviewed June 2024; adult treatment criteria checked Oct 17, 2026
• Lilly Medical — Retatrutide expanded access, last reviewed Aug 26, 2026; checked Oct 17, 2026
• ClinicalTrials.gov — NCT07629401 (expanded access), record updated Aug 6, 2026, and NCT07165028 (SYNERGY-Outcomes), record updated Oct 8, 2026; records checked Oct 17, 2026
• Eli Lilly — Trial finder and What to know about retatrutide; checked Oct 17, 2026
• FDA — Concerns with unapproved GLP-1 drugs used for weight loss, content current Oct 1, 2026; checked Oct 17, 2026
• FDA — Off-label use, compounding questions and answers, and expanded access for patients; checked Oct 17, 2026
• FDA — PDUFA review goals, fiscal years 2023–2027, sections I.A.1 and I.B.4; checked Oct 17, 2026
• Eli Lilly — Zepbound prescribing information, revised Aug 2026, and Foundayo prescribing information; checked Oct 17, 2026
• Novo Nordisk — Wegovy prescribing information and Ozempic prescribing information, Ozempic revised May 2026; checked Oct 17, 2026
• Manufacturers — Zepbound savings terms, Foundayo savings terms, and NovoCare Wegovy savings terms; checked Oct 17, 2026
• Medicare — Weight-loss drug coverage; checked Oct 17, 2026
• Poison Control — First aid for poisonings; checked Oct 17, 2026